pharmaceutical pricing
Value-Based Pricing in 2012 – Is it Still Worth the Trouble?
February 08 by Stuart Carroll & Alasdair WilliamsAs the old aphorism goes, a New Year means a new beginning. It also provides an opportunity for all of us to make New Year resolutions – promises we make to one or more lasting personal goals, p...
Are Orphan Drugs Still a Licence to Print Money?
July 20 by Andrea CharlesIn this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fun...
Korea’s Pricing Policy and Medical Tourism
May 26 by Cyrus ChowdhuryKorea’s metamorphosis from emerging to mature Korea has come a long way since the country moved to a single-payer system by merging hundreds of independent insurance societies. Reforms in...
EU Accession Reference Pricing
September 28 by Pharmaceuticals & Biotechnology EditorInternational reference pricing has grown from an evolving cost-containment philosophy in Western Europe, to a trusted policy tool readily adopted by emerging markets around the world. As, Cro...
EU Price-Cut Pandemic: Managing with Discipline
July 01 by Cyrus ChowdhuryRecent weeks have revealed the immediate result of the European debt crisis: adoption of austerity measures, many of which prioritise an easy target, pharmaceutical expenditure. Governments tend...